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a b s t r a c t
To clarify the cellular mechanisms for the establishment of prion infection, we analyzed the intracellular
dynamics of inoculated and newly generated abnormal isoform of prion protein (PrPSc) in Neuro2a cells.
Within 24 h after inoculation, the newly generated PrPSc was evident at the plasma membrane, in early
endosomes, and in late endosomes, but this PrPSc was barely evident in lysosomes; in contrast, the
majority of the inoculated PrPSc was evident in late endosomes and lysosomes. However, during the
subsequent 48 h, the newly generated PrPSc increased remarkably in early endosomes and recycling
endosomes. Overexpression of wild-type and mutant Rab proteins showed that membrane trafﬁcking
along not only the endocytic-recycling pathway but also the endo-lysosomal pathway is involved in de
novo PrPSc generation. These results suggest that the trafﬁcking of exogenously introduced PrPSc from the
endo-lysosomal pathway to the endocytic-recycling pathway is important for the establishment of prion
infection.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Prions are causative agents of transmissible spongiform encepha-
lopathies (TSEs), neurodegenerative disorders that are characterized
by accumulation of an abnormal isoform of prion protein (PrPSc) in the
central nervous system (CNS). PrPSc is the only known proteinaceous
component of prions, and infectivity of prions is thought to be
associated with PrPSc oligomers (Silveira et al., 2005; Wang et al.,
2010). PrPSc is a conformational isomer of a cellular prion protein
(PrPC) and is rich in β-sheet; PrPSc is generated from PrPC, a protein
that is expressed on the surface of host cells (Prusiner, 1998).
Conversion of PrPC to PrPSc is thought to be triggered by direct contact
between “seed” PrPSc and “substrate” PrPC.
The intracellular dynamics of PrPSc immediately following
exposure of the cells to prions have been analyzed to understand
the mechanisms by which a prion infection becomes established.
Although PrPC is not necessary for the internalization of PrPSc
(Greil et al., 2008; Hijazi et al., 2005; Jen et al., 2010; Magalhaes
et al., 2005; Paquet et al., 2007), some candidates such as laminin
receptor, heparan sulfate, or low-density lipoprotein receptor-
related protein 1 (LRP1) have been reported to act as receptors
that mediate internalization of exogenously inoculated PrPSc
(Gauczynski et al., 2006; Horonchik et al., 2005; Jen et al., 2010).
During the early stage after inoculation of PrPSc, internalized
PrPSc has been reported to be directed to late endosomes/lyso-
somes via the endo-lysosomal pathway (Jen et al., 2010;
Magalhaes et al., 2005). In cells persistently infected with prions,
a number of studies have shown that PrPSc localizes throughout
the endocytic compartments—speciﬁcally the plasma membrane,
early endosomes, recycling endosomes, late endosomes, secondary
lysosomes, and the peri-nuclear Golgi region (Marijanovic et al.,
2009; McKinley et al., 1991; Pimpinelli et al., 2005; Taraboulos
et al., 1990; Veith et al., 2009; Vey et al., 1996; Yamasaki et al.,
2012). Earlier studies suggested that the generation of PrPSc occurs
on the cell surface or within the endocytic pathway (Borchelt et al.,
1992; Caughey and Raymond, 1991; Taraboulos et al., 1992).
Marijanovic et al. reported that the endocytic recycling compart-
ment (ERC) may be the site where the conversion of PrPC to PrPSc
occurs (Marijanovic et al., 2009). In a very early stage of prion
infection where new PrPSc formation was measured within min-
utes after initiation of infection, Goold et al. recently reported that
the plasma membrane is a primary site of conversion (Goold et al.,
2011).
In spite of the efforts described above, the events required for
the establishment of prion infection in cells, especially those that
occur in the early stage after introduction of the infectious prions,
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are poorly understood. Simultaneous analysis of inoculated PrPSc
and newly generated PrPSc in a short period after challenge with
prions is important for understanding the early events of prion
infection. However, such analysis is limited due to the technical
difﬁculties in the distinction of PrPSc from PrPC and also in the
distinction of newly generated PrPSc from inoculated PrPSc. For
example, antibody epitope-tagging has been used to speciﬁcally
detect host cell-derived PrP or input PrPSc (Greil et al., 2008;
Vorberg et al., 2004) but not both. Speciﬁc labeling of PrPSc with
anti-PrP antibody via pre-treatment of cells with chaotropic agents
such as guanidinium salt has been widely used to detect PrPSc in
cells (Marijanovic et al., 2009; Pimpinelli et al., 2005; Taraboulos
et al., 1990). However, this method is limited because weak PrPSc
signals such as newly generated PrPSc may be lost or obscured
because the detector gain or exposure times need to be adjusted to
a level at which signals from endogenous PrPC are below the
detection limit.
We recently reported that mAb 132, an anti-PrP monoclonal
antibody that recognizes an epitope consisting of amino acids 119–
127 of mouse PrP, allowed us to visualize PrPSc in prion-infected
cells by indirect immunoﬂuorescence assay (IFA) without speciﬁc
manipulation of threshold setting to diminish PrPC signals
(Yamasaki et al., 2012). Here, we established a method in which
inoculated PrPSc and newly generated PrPSc can be distinguished
by combining the use of ﬂuorescent-dye-labeled puriﬁed protei-
nase K (PK)-resistant PrPSc (PrP-res) as inoculum with PrPSc-
speciﬁc staining with mAb 132. By using this method, in the
present study, we extensively analyzed the fate of the inoculated
PrP-res and the appearance of newly generated PrPSc in Neuro2a
cells during the early stages of prion infection.
Fig. 1. Characterization of puriﬁed PrP-res. (a) Purity of the PrP-res preparation. Puriﬁed PrP-res fractions from the brains of mice infected with the Obihiro strain (Obi-PrP-
res) and the 22 -L strain (22-L-PrP-res) were subjected to SDS-PAGE followed by silver staining and immunoblotting with mAb 31C6. (b) Purity of ﬂuorescent-dye-labeled
PrP-res. The puriﬁed 22-L-PrP-res was labeled with Alexa Fluor 488 (Af488-22-L-PrP-res) or Alexa Fluor 555 (Af555-22-L-PrP-res). Purity and ﬂuorescent-dye-labeling were
analyzed with silver staining, immunoblotting with mAb 31C6, and ﬂuorescence imaging. (c) Inﬂuence of sonication on puriﬁed PrP-res. Puriﬁed 22-L-PrP-res was sonicated
and then before and after centrifugation at 10,000  g for 10 min [supernatant (Sup), precipitate (Ppt)] the PrP-res was subjected to immunoblotting with mAb 31C6.
(d) PrPSc-speciﬁc staining of cells inoculated with PrP-res. N2a-3 cells were incubated with Af555-22-L-PrP-res for 6 h at 37 1C, and then subjected to PrPSc-speciﬁc staining.
The top panel shows the images of PrPSc detected with mAb 132 (green, left) and Af555-22-L-PrP-res (red, center), and their merged image (right). The bottom panel shows
the corresponding high-magniﬁcation images of the boxed regions. Cells were counterstained with DAPI (blue). Scale bar: 10 mm.
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Results
Puriﬁcation and labeling of PrP-res
To monitor the intracellular dynamics of PrP-res after inocula-
tion, PrP-res was puriﬁed from the brains of mice infected with the
22-L or Obihiro scrapie strain and the puriﬁed PrP-res was labeled
with Alexa Fluor 488 or Alexa Fluor 555 succinimidyl ester. Silver
staining and immunoblotting of the labeled and unlabeled pre-
parations showed the expected three major bands ranging from 35
to 20 kDa corresponding to the three PrP glycoforms, demonstrat-
ing purity of the PrP-res fraction (Fig. 1a and b). However, both
preparations contained bands less than mol wt 15 kDa that did not
react with mAb 31C6 (Fig. 1a). Fluorescence imaging, as well as
silver staining and immunoblotting of Alexa Flour 488- or 555-
labeled puriﬁed PrP-res (Af488-22-L-PrP-res or Af555-22-L-PrP-
res, respectively), revealed that the purity was satisfactory for the
analysis of intracellular trafﬁcking of 22-L-PrP-res by ﬂuorescent
microscopy (Fig. 1b). The size of PrPSc aggregates inﬂuences the
uptake of PrPSc into cells (Greil et al., 2008; Jen et al., 2010;
Magalhaes et al., 2005); therefore, the 22-L-PrP-res was exten-
sively sonicated and large aggregates were removed by centrifuga-
tion. The PrP-res that largely remained in the supernatant (Fig. 1c)
was used as the inoculum for N2a-3 cells, a Neuro2a clone which is
susceptible to prion infection (Uryu et al., 2007). As was the case in
previous studies (Jen et al., 2010; Magalhaes et al., 2005), the
Af555-22-L-PrP-res that was internalized by cells was dynamically
moving throughout the cells at 6 h after inoculation (Supplemen-
tary video 1). Most of the Af555-22-L-PrP-res particles were co-
localized with PrPSc signals by immuno-staining with mAb 132
(Fig. 1d), which demonstrated the utility of detection of Alexa
Fluor 555 signals for monitoring the trafﬁcking of inoculated PrP-
res by ﬂuorescence microscopy.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.virol.2013.11.007.
Intracellular localization of inoculated PrP-res
To analyze the intracellular trafﬁcking of the inoculated PrP-res,
particularly in the very early stages after internalization, trafﬁcking
of the Af555-22-L-PrP-res was monitored in cells that transiently
express enhanced green ﬂuorescent protein (EGFP)-tagged wild-
type Rab4a, 5a, 7, 9, 11a, or 22a as markers of distinct endocytic
compartments as follows: Rab4a, early endosomes including rapid
endocytic recycling endosomes; Rab5a, early endosomes; Rab7,
late endosomes; Rab9, late endosomes involved in retrograde
transport to the trans-Golgi network (TGN); Rab11a, recycling
endosomes; Rab22a, early endosomes involved in transport to
recycling endosomes and TGN (Stenmark, 2009). To reduce the
possibility of observing ectopically targeted Rab GTPase-EGFP
fusion proteins, cells showing relatively weak EGFP signals were
selected for these observations. Within 2 h after the initiation of
incubation with Af555-22-L-PrP-res, we observed particles of
Af555-22-L-PrP-res that were incorporated into the EGFP-
positive vesicles and thereafter, PrP-res particles moved together
with the EGFP-positive vesicles throughout the cells. These
dynamics were observed in cells that expressed any type of Rab
GTPase-EGFP fusion protein (Fig. 2, arrows). These observations
indicated that exogenously introduced PrP-res was most likely
transported throughout endocytic compartments within a short
period after internalization.
Transferrin (Tfn) binds to the Tfn receptor, which is internalized
from the cell surface by clathrin-coated pits, transported to early
endosomes and then recycled back to the plasma membrane via
the ERC (Maxﬁeld and McGraw, 2004). In contrast, low-density
lipoprotein (LDL) binds to the LDL receptor, which is also
internalized from the cell surface via clathrin-coated pits; how-
ever, after dissociation from the LDL receptor in early endosomes,
LDL is transported to late endosomes for degradation (Ikonen,
2008). Herein we deﬁne the pathway by which the Tfn receptor is
recycled between the plasma membrane and the ERC as “endocy-
tic-recycling pathway” and the pathway by which LDL is directed
to late endosomes or lysosomes for degradation as “endo-lysoso-
mal pathway”. To analyze the trafﬁcking of PrP-res immediately
after internalization, Af555-22-L-PrP-res and Alexa Fluor 488-
conjugated Tfn (Af488-Tfn) or Alexa Fluor 488-conjugated LDL
(Af488-LDL) were inoculated simultaneously into N2a-3 cells.
Time-lapse imaging showed that within 2 h after the initiation of
incubation with PrP-res, a particle of Af555-22-L-PrP-res on the
cell surface was internalized and merged with Af488-Tfn signals
(Fig. 3a, between 1 min 40 s and 4 min 30 s) during transport to a
peri-nuclear region, and thereafter, Af555-PrP-res and Af488-Tfn
moved together back to a peripheral region of the cell (e.g., 10 min
20 s). We also observed internalization of an Af555-22-L-PrP-res
particle from the cell surface that subsequently merged with an
Af488-LDL-positive vesicle (Fig. 3b, between 7 min 50 s and 9 min
5 s), and thereafter, Af555-PrP-res and Af488-LDL moved together
(e.g., 10 min 5 s).
To clarify the trafﬁcking pathway of the inoculated PrP-res, cells
incubated with Af555-22-L-PrP-res for 6 h were subsequently
cultured for up to 30 h. Six hours after the incubation with PrP-
res, some of the Af555-22-L-PrP-res signals co-localized with the
Af488-Tfn signal not at the center of the cluster of the Af488-Tfn
signal, but at a region around the cluster (Fig. 3c, Tfn, 0 h). On the
other hand, a large portion of the Af555-22-L-PrP-res appeared to
co-localize with Af488-LDL throughout the cells (Fig. 3c, LDL, 0 h).
Quantitative analysis of the co-localization revealed that Af555-
22-L-PrP-res co-localized more with Af488-LDL (53%) than AF488-
Tfn (26%). The co-localization of Af555-22-L-PrP-res with Af488-
LDL was still obvious (49%) 30 h after the inoculation, whereas, the
co-localization of Af555-22-L-PrP-res with Af488-Tfn had appar-
ently decreased (4%) (Fig. 3c, LDL and Tfn, 30 h). These results
suggested that internalized PrP-res entered both the endocytic-
recycling pathway and the endo-lysosomal pathway immediately
following internalization, but a large portion of the inoculated PrP-
res was eventually directed to the endo-lysosomal pathway.
The kinetics of inoculated PrP-res metabolism and generation of PrPSc
To determine the fate of the inoculated PrP-res and detect de
novo generation of PrPSc, the PrP-res level in cells inoculated with
Af488-22-L-PrP-res was analyzed with immunoblotting. The level
of inoculated Af488-22-L-PrP-res, which was detected with an
anti-Alexa Fluor 488 antibody, was drastically decreased within
24 h post inoculation (hpi) (Fig. 4a). In contrast, the total PrP-res
level, which was detected with an anti-PrP antibody reactive to
both the inoculated PrP-res and newly generated PrPSc, was
unchanged at 24 hpi but increased thereafter (Fig. 4a). The
decrease in the inoculated PrP-res was also consistent with the
decrease in the PrP-res signal observed by live-cell imaging of
Af555-22-L-PrP-res over the same time period (Fig. 4b). The
increase of the mono-glycosylated PrP-res on immunoblots of
total PrP-res at 24 hpi suggested that the de novo generation of
PrPSc takes place within 24 hpi (Fig. 4a, arrowhead). Therefore, we
analyzed the inoculated PrP-res and newly generated PrPSc simul-
taneously in individual cells by IFA. We used Af555-22-L-PrP-res in
combination with mAb 132-mediated speciﬁc detection of PrPSc to
distinguish de novo PrPSc, which could be detected only with mAb
132 (Fig. 4c, arrows), from exogenous PrP-res, which was labeled
with both Alexa Fluor 555 and mAb 132 (Fig. 4c, arrowheads).
Signals from newly generated PrPSc became detectable at 24 hpi,
especially at a peri-nuclear region of the cells (arrows), and the
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number of newly generated PrPSc granules and their ﬂuorescent
intensities increased thereafter. In contrast to the increase of
newly generated PrPSc, the inoculated PrP-res decreased with time
(Fig. 4c, arrowheads).
Intracellular localization of inoculated PrP-res and newly generated
PrPSc
To identify the site of de novo generation of PrPSc, we next
analyzed the intracellular localization of inoculated Af555-22-L-
PrP-res and newly generated PrPSc with markers for endocytic
compartments. At 24 hpi, some ﬂuorescent signals from the newly
generated PrPSc co-localized well with EEA1 (early endosomes)
and Rab7 (late endosomes), but were poorly co-localized with
Rab11a (recycling endosomes) or cathepsin D (lysosomes) (Fig. 5).
Furthermore, faint signals from newly generated PrPSc could be
detected at the cell surface at 24 hpi. The intensities of these PrPSc
signals increased with time after inoculation (Fig. 5, from 24 to
72 hpi). In order to clarify the kinetics of distribution of the
inoculated PrP-res and newly generated PrPSc, we quantitatively
analyzed co-localization ratios of the inoculated PrP-res and newly
generated PrPSc co-localized with markers (Fig. 6). Consistent with
the data from the live-cell imaging (Fig. 3), a large proportion of
the inoculated PrP-res localized to late endosomes (40%) while a
smaller portion was detected at the cell surface (22%) at 0 hpi.
The exogenous PrP-res at the cell surface almost disappeared
Fig. 2. Intracellular localization of ﬂuorescent-dye-labeled, puriﬁed-PrP-res. N2a-3 cells grown on chambered coverglass were transfected with expression plasmids of EGFP-
tagged wild-type of Rab4a, 5a, 7, 9, 11a or 22a. Medium (200 μl) containing 10 ng of Af555-22-L-PrP-res was added to cells 72 h after transfection. Time series of images were
acquired any of 15 min-duration (images were acquired every 5 s within 2 h after the initiation of incubation with Af555-22-L-PrP-res. Each image in a row shows a merged
image of Af555-22-L-PrP-res (red) and EGFP-Rab GTPase (green) with differential interference contrast (DIC) at the indicated time point. Arrows indicate examples of Af555-
22-L-PrP-res that became co-localized with EGFP-Rab GTPases during the period of observation. Scale bar: 5 μm.
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during the subsequent 48 h and the remaining PrP-res localized to
late endosomes (from 16% to 14%) and lysosomes (from 11% to 9%).
In contrast, at 24 hpi newly generated PrPSc localized mainly at the
cell surface (27%), in early endosomes (15%), and late endosomes
(30%), but a minor portion localized to lysosomes (3%). Interest-
ingly, the proportion of newly generated PrPSc localized to early
endosomes or recycling endosomes increased (from 15% to 30%
and from 5% to 33%, respectively); in contrast, the amount of
PrPSc at the cell surface decreased from 27% to 3% with time
after inoculation. These data suggested that even though newly
generated PrPSc was detected in late endosomes and lysosomes
at 24 hpi, newly generated PrPSc remarkably appeared in the
intracellular organelles on the endocytic-recycling pathway
thereafter.
Fig. 3. Co-localization of Af555-22-L-PrP-res with Tfn or LDL. Time-lapse imaging of inoculated PrP-res and Af488-Tfn (a) or Af488-LDL (b). N2a-3 cells grown on chambered
coverglass were incubated with Af555-22-L-PrP-res (red) and 10 μg/ml of Af488-Tfn (green) as a marker of the endocytic-recycling pathway (a) or 4 μg/ml of Af488-LDL
(green) as a marker of the endo-lysosomal pathway (b). Time-lapse images were acquired any of 15 min-duration (images were acquired every 5 s) within 2 h after the
initiation of incubation with PrP-res. Each image within a row shows a merged image of Af555-22-L-PrP-res (red) and Af488-Tfn or Af488-LDL (green) with the DIC at the
indicated time point. Arrows indicate examples of Af555-22-L-PrP-res that became co-localized with Af488-Tfn (a) or Af488-LDL (b) in the period of observation. (c) Co-
localization of Af555-22-L-PrP-res with Af488-Tfn or Af488-LDL. N2a-3 cells were incubated with Af555-22-L-PrP-res and Af488-Tfn or Af488-LDL for 6 h at 37 1C. After the
removal of excess Af555-22-L-PrP-res, the cells were subjected to live-cell imaging (0 h). To monitor co-localization of PrP-res one day after inoculation, N2a-3 cells were
incubated with Af555-22-L-PrP-res for 6 h. After the removal of excess Af555-22-L-PrP-res, the cells were further incubated for 24 h at 37 1C. The cells were then incubated
for an additional 6 h in the presence of Af488-Tfn or Af488-LDL before imaging (30 h). The right-most column shows the merged images of Af488-Tfn (green) or Af488-LDL
(green), Af555-22-L-PrP-res (red), and DIC. Arrows indicate examples of Af555-22-L-PrP-res co-localized with Af488-Tfn or Af488-LDL. Scale bar: 5 μm. The graph on the
right shows ratios of Af555-22-L-PrP-res signals co-localized with Af488-Tfn or Af488-LDL signals relative to sum of the Af555-22-L-PrP-res signals (methods for the
calculation of the co-localization ratio are described in the Supplementary information). Mean and SD of the values acquired from 15 ﬁelds of view are depicted. Total
numbers of foci and cells used for co-localization statistics from the 15 view ﬁelds were listed in Table S4.
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Inﬂuence of the impairment of intracellular transport on de novo
generation of PrPSc
To determine which pathway of intracellular transport is
involved in de novo generation of PrPSc, we analyzed the levels
of newly generated PrPSc in cells in which trafﬁcking between
the endocytic compartments was selectively impaired by the
overexpression of wild-type or dominant-negative mutants of
Rab GTPase proteins (Fig. 7). The impairment of the endocytic-
recycling pathway by overexpression of wild-type Rab22a or a
dominant-negative mutant of Rab11a, which are known to affect
the transport from early endosomes to recycling endosomes
(Magadan et al., 2006) or the transport from recycling endosomes
to plasma membrane (Ren et al., 1998), respectively, reduced the
Fig. 4. Kinetics of inoculated PrP-res and de novo generation of PrPSc. (a) The levels of inoculated PrP-res and total PrP-res. N2a-3 cells grown on 12-well plates were
inoculated with Af488-22-L-PrP-res. After the inoculation, the cells were cultured for the indicated period and then subjected to immunoblotting. As a control for detection
of PrP-res, mock-infected cells were prepared (M). PK-untreated samples equivalent to 100 μg of total protein per lane were loaded to detect Af488-22-L-PrP-res with anti-
Alexa Fluor 488 antibody (Alexa), while PK-digested samples equivalent to 100 μg of total protein were also loaded to monitor total PrP-res, which contained inoculated PrP-
res and newly generated PrP-res with anti-PrP mAb 31C6 (PrP-res). β-actin was used as an internal control. Bands corresponding to monomeric and dimeric PrPSc (indicated
by the square bracket) were quantiﬁed. The arrowhead indicates the mono-glycosylated form of PrP-res. The graph on the right shows the result of a quantitative analysis.
Black bars indicate the inoculated PrP-res levels relative to that at 0 h and gray line indicates the total PrP-res levels relative to that at 0 h. Mean and SD of 3 independent
experiments are shown. (b) Live-cell image of Af555-22-L-PrP-res. N2a-3 cells grown on chambered coverglass were inoculated with Af555-22-L-PrP-res and then cultured
for the indicated time. Merged images containing Af555-22-L-PrP-res (red) and DIC are shown. (c) Discrimination of newly generated PrPSc from inoculated PrP-res in a
single cell. The top panel shows the merged images of signals of Af555-22-L-PrP-res (red), PrPSc (green) and DAPI-stained nuclei (blue). The bottom panel shows the
corresponding high-magniﬁcation images of the boxed region. Arrowheads indicate examples of inoculated PrP-res that was detected via both Alexa Fluor 555 (red, directly
coupled to puriﬁed 22-L-PrP-res) and mAb 132 (green, indirect immuno-staining with Alexa Fluor 488-conjugated secondary antibody). As a result, inoculated PrP-res can be
detected as yellow. Arrows indicate examples of newly generated PrPSc that was detected only with mAb 132 (green). Scale bar: 5 μm.
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Fig. 5. Kinetics of the intracellular localization of inoculated PrP-res and newly generated PrPSc. N2a-3 cells inoculated with Af555-22-L-PrP-res were cultured for the indicated
time and subjected to double-staining of PrPSc with mAb 132 and an organelle marker molecule as indicated. For staining of PrPC at cell surface, cells were incubated with B103
antiserum prior to the ﬁxation for PrPSc-speciﬁc detection. Alexa Fluor 647-conjugated secondary antibody was used to stain the marker molecules. The cell nuclei were
counterstained with DAPI. The upper left image in each panel consists of four images shows a lower magniﬁcation view of a merged image of organelle marker molecule (red),
PrPSc (green), Af555-22-L-PrP-res (cyan), and nuclei (blue). The other three images are the corresponding high-magniﬁcation image of the boxed region for the merged image of
organelle marker and nuclei (bottom left), for the merged image of PrPSc, Af555-22-L-PrP-res and nuclei (upper right), and for the merged images of the organelle marker, PrPSc,
Af555-22-L-PrP-res and nuclei (bottom right). Arrowheads indicate representative co-localization of Af555-22-L-PrP-res with organelle marker molecules, while arrows indicate
that of newly generated PrPSc with organelle marker molecules. Arrowheads with asterisks indicate AF555-22-L-PrP-res that was not co-localized with organelle marker
molecules, while arrows with asterisks indicate newly generated PrPSc that was not co-localized with organelle marker molecules. Co-localization areas were deﬁned as pixels
that were positive for both PrPSc and organelle marker signals, or that were positive for both Af555-22-L-PrP-res and organelle marker signals. Scale bars: 5 μm.
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amount of de novo generated PrPSc at 48 hpi by 62% or 69% of
the control (Fig. 7). Additionally, the impairment of the endo-
lysosomal pathway by the overexpression of a dominant-negative
mutant of Rab7, which is known to affect the transport from early
endosomes to late endosomes and/or lysosomes (Bucci et al.,
2000; Feng et al., 1995), also reduced the amount of de novo
generated PrPSc at 48 hpi by 60% of the control (Fig. 7). A wild-type
Rab9 is reported to be involved in the transport from late
endosomes to TGN (Riederer et al., 1994). The overexpression of
wild-type Rab9 reduced the amount of de novo generated PrPSc by
71% of the control; however, it was not clear which intracellular
transport pathway was actually inﬂuenced (Fig. 7). The level of
endogenous PrPC in cells and cell-surface expression of PrPC were
not altered by overexpression of wild-type Rab9, wild-type
Rab22a, a dominant-negative Rab7 mutant, or a dominant-
negative Rab11a (Supplementary Fig. 1). Taken together, these
results indicated that the inhibition of de novo generation of PrPSc
was not caused by a change in the expression of PrPC. These data
suggested that intracellular transport along the endocytic-
recycling pathway as well as the endo-lysosomal pathway is
involved in the de novo generation of PrPSc after the inoculation
of PrP-res.
Discussion
The lack of a method that can distinguish newly generated
PrPSc from endogenous PrPC and from inoculum-derived PrPSc was
one of the obstacles to the investigation of the cellular events that
mediate the de novo generation of PrPSc in the early stage of prion
infection. Therefore, the analysis of intracellular dynamics of PrPSc
just after inoculation of prions has been limited to inoculum-
derived PrPSc as descried previously (Jen et al., 2010; Magalhaes
et al., 2005). Here, we solved this problem with a combination of
the ﬂuorescent-dye-labeled puriﬁed PrP-res and PrPSc-speciﬁc
staining with mAb 132. This technique allowed us to distinguish
Fig. 7. Effect of overexpression of Rab GTPases on the de novo generation of PrPSc. N2a-3 cells grown in a 24-well plate were inoculated with unlabeled 22-L-PrP-res and
were incubated for 6 h. After washing the cells, an expression plasmid encoding an EGFP-tagged wild-type (Wt) Rab GTPase, Rab4a, Rab5a, Rab7, Rab9, Rab11a or Rab22a, or
an EGFP-tagged dominant-negative mutant (DN) of a Rab GTPases, Rab4aS22N (Roberts et al., 2001), Rab5aS34N (Stenmark et al., 1994), Rab7T22N (Feng et al., 1995),
Rab9S21N (Riederer et al., 1994), Rab11aS25N (Ren et al., 1998) or Rab22aS19N (Weigert et al., 2004), was introduced. The expression vector pEGFP-C1 (Clontech) was used as
a control. At 48 h after transfection, the cells were processed for dot-blotting to monitor PrP-res. A representative image of a dot-blot is shown on the top, and the graph
below shows the levels of PrP-res relative to that of control plasmid-transfected cells (EGFP). Mean and SD of 4 independent experiments are depicted. Asterisks indicate a
signiﬁcant decrease compared to the control (Student's t-test, po0.05).
Fig. 6. Co-localization statistics. Co-localization analysis of the images shown in
Fig. 5 was carried out as described in the Supplementary materials. (a) Ratio of the
Af555-22-L-PrP-res signals co-localized with each marker to the sum of the Af555-
22-L-PrP-res signals. (b) Ratio of the newly generated PrPSc signals co-localized
with each marker to the sum of newly generated PrPSc signals. Mean and SD of the
value acquired in 5 ﬁelds of view are shown. Total numbers of foci and cells used
for co-localization statistics from the 5 view ﬁelds were listed in Table S5.
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newly generated PrPSc from the inoculated PrP-res within
individual cells.
Considering that the inoculated PrP-res was mainly detected in
late endosomes and lysosomes (Figs. 5 and 6) and that its levels
decreased from 24 to 72 h after the inoculation (Fig. 4), the PrP-res
directed to the endo-lysosomal pathway appeared to be degraded
in late endosomes and/or lysosomes. Previous studies showed that
inoculated PrP-res is transported to late endosomes/lysosomes
after being taken up by SN56 cells or primary sensory neurons (Jen
et al., 2010; Magalhaes et al., 2005). Puriﬁed PrP-res of the Obihiro
strain, which cannot establish a persistent infection in N2a-3 cells,
was also transported to late endosomes and lysosomes; the
intracellular distribution of Alexa Fluor-labeled Obihiro strain-
derived PrP-res was indistinguishable from that of the 22-L
strain-derived PrP-res and the inoculated PrP-res of Obihiro strain
was degraded similarly to 22-L strain-derived PrP-res (data not
shown). Amyloid ﬁbrils of the Aβ1-42 peptide were also reported
to be transported via the endo-lysosomal pathway in SN56 cells
(Magalhaes et al., 2005). Taken together, the trafﬁcking of PrP-res
via the endo-lysosomal pathway appears to be a general pathway
for degradation of exogenously introduced macromolecules, rather
than a pathway speciﬁc to PrPSc and the propagation of prions
(Saftig and Klumperman, 2009).
Recently, Goold et al. reported that the plasma membrane is
one of the sites for conversion based on the results from experi-
ments using PK-1 cells that express PrPC tagged with Myc-epitope
at the C-terminus (Goold et al., 2011). In this report, PrPSc was
primarily generated at the plasma membrane within 2 min after
prion challenge. Contrary to this report, we found no evidence that
de novo generation of PrPSc primarily occurred at plasma mem-
brane (Figs. 4–6). This discrepancy may be due to multiple factors,
one of which includes clonal differences between these cell lines.
For example, the former study showed that newly generated PrPSc
attained steady levels by 2 h after inoculation of prions and
approximately 20% of PK-1 cells in the cultures became PrPSc-
positive. However, in the N2a-3 cells used in our study, the levels
of newly generated PrPSc in the cells increased at least up to 72 hpi
(Fig. 4), and most of the cells in the culture eventually became
PrPSc-positive (data not shown). In addition, Goold et al. reported
that PrPSc was detected at the cell membrane of prion-infected PK-
1 cells; however, PrPSc was only weakly detected at the plasma
membrane of N2a-3 cells persistently infected with prions, even
when formic acid pre-treatment that was used for PrPSc-speciﬁc
detection by Goold et al. was employed (data not shown). Finally,
the differences between the two studies might be accounted for
the different inocula (puriﬁed PrP-res vs. brain homogenate) used
to initiate infection.
Most PrPC is known to cycle between a peri-nuclear region of
the cell and the plasma membrane via the endocytic-recycling
pathway after being trafﬁcked to the cell surface, but some portion
of PrPC is also delivered to late endosomes and lysosomes (Morris
et al., 2006; Peters et al., 2003; Shyng et al., 1993). Considering
that the newly generated PrPSc appeared in late endosomes, but
was rarely observed in lysosomes at 24 hpi, at which time a large
portion of the inoculated PrP-res was localized in late endosomes
(Figs. 5 and 6), the initial conversion of PrPC to PrPSc may occur in
late endosomes, at least when puriﬁed PrP-res is used as an
inoculum. This idea is consistent with the ﬁnding that overexpres-
sion of the dominant-negative mutant of Rab7, which inhibits
transport from early endosomes to late endosomes and/or lyso-
somes (Bucci et al., 2000; Feng et al., 1995), partly inhibited the
generation of PrPSc after the inoculation of PrP-res (reduced to 60%
of the control, Fig. 7). This ﬁnding raises the possibility that
although most of the inoculated PrP-res was transported to and
degraded in late endosomes/lysosomes, smaller PrP-res oligomers
might be generated in late endosomes during the degradation
process. Such smaller PrP-res oligomers may initiate PrPC conver-
sion because smaller oligomers have greater seeding activity for
the conversion of PrPC and higher infectivity than larger PrP-res
aggregates (Silveira et al., 2005).
Earlier studies suggested that in cells persistently infected with
prions, PrPSc is formed either on the plasma membrane or during
endocytic trafﬁcking (Borchelt et al., 1992; Caughey and Raymond,
1991; Taraboulos et al., 1992). In later years, Béranger et al. and
Marijanovic et al. reported that overexpression of dominant-
negative mutants of Rab4a or Rab11a, which are known to impair
the transport from early endosomes to the plasma membrane
(Roberts et al., 2001) or from recycling endosomes to the plasma
membrane (Ren et al., 1998), respectively, raised the PrPSc level
(Beranger et al., 2002; Marijanovic et al., 2009). On the other hand,
overexpression of wild-type Rab22a, which inhibits the transport
from early endosomes to recycling endosomes (Magadan et al.,
2006), reduced the PrPSc level in cells persistently infected with
prions (Marijanovic et al., 2009). Based on these ﬁndings, one of
the sites for PrPSc formation in cells persistently infected with
prions is thought to be in the transport pathway from early
endosomes to recycling endosomes. Also in the early stage of
prion infection, we conﬁrmed the inhibition of de novo generation
of PrPSc by overexpression of a wild-type Rab22a (reduced to 69%
of the control, Fig. 7), consistent with the results of Marijanovic
et al. in persistently prion-infected cells (Marijanovic et al., 2009).
However, unlike the ﬁndings in cells persistently infected with
prions, the generation of PrPSc after the inoculation of PrP-res was
partly inhibited by overexpression of a dominant-negative Rab11a
mutant (reduced to 62% of the control, Fig. 7). These observations
suggested that the initiation of PrPSc generation shortly after PrP-
res inoculation required the recycling pathway between recycling
endosomes and the plasma membrane. Further studies will be
required to explain the apparent inconsistency between these
results. However, the newly generated PrPSc appeared at the
plasma membrane and in early endosomes where the inoculated
PrP-res was rarely detected at 24 hpi (Figs. 5 and 6), suggesting
the involvement of the recycling pathway; therefore, either
the exogenous PrP-res degraded to an undetectable level or PrPSc
newly generated in late endosomes was recycled back to the
plasma membrane and acted as a “seed” for conversion. Moreover,
the marked increase in the newly generated PrPSc at early and
recycling endosomes during the following 48 h (Figs. 5 and 6)
suggested that efﬁcient generation of PrPSc occurred once the PrPSc
was transferred to the endocytic-recycling pathway.
The results in this study suggest that the transfer of the
inoculated PrP-res and/or newly generated PrPSc from the endo-
lysosomal pathway to the endocytic-recycling pathway is impor-
tant for efﬁcient PrPSc formation after prion inoculation. One
possible route of such transfer is the trafﬁcking from the late
endosomes to the plasma membrane through the TGN, a route by
which cation-independent mannose-6-phosphate receptor
(CIMPR) is transported (Maxﬁeld and McGraw, 2004). CIMPR
delivers hydrolase precursors from the Golgi apparatus to the
endosomes and releases hydrolases into compartments in the
process of late endosome formation; CIMPR is then recycled back
from late endosomes to the TGN by retrograde transport. CIMPR in
the TGN is also delivered to the plasma membrane (Ghosh et al.,
2003). The overexpression of Rab9, which is involved in this
retrograde transport of CIMPR (Riederer et al., 1994), was reported
to decrease the levels of PrPSc in cells persistently infected with
prions (Gilch et al., 2009) as well as inhibit the generation of PrPSc
after prion inoculation (this study), suggesting that the trafﬁcking
from late endosomes to the TGN may be involved in the genera-
tion of PrPSc.
Direct transport from late endosomes to the plasma membrane
might be an alternative route. This atypical transport was reported
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in the trafﬁcking of class II molecules of the major histocompat-
ibility complex (MHC) and CD1 family molecules in antigen-
presenting cells (Gelin et al., 2009; Neefjes et al., 2011). Further-
more, MHC class II molecules are also known to be transported in
the process of exosomes release (Berger and Roche, 2009; Von
Bartheld and Altick, 2011). Considering the fact that PrPC is present
on the membranes of both multivesicular bodies and intraluminal
vesicles and that PrPSc as well as PrPC are released from cells with
exosomes (Fevrier et al., 2004), the inoculated PrP-res and/or
newly generated PrPSc in late endosomes may be recycled back
to the plasma membrane through multivesicular bodies via a
pathway similar to the MHC class II molecules. This idea is
consistent with the ﬁnding that de novo generation of PrPSc was
inhibited by the overexpression of the dominant-negative Rab11a
mutant, which also inhibits the release of exosomes (Savina et al.,
2002). The PrPSc recycled to the plasma membrane via these
mechanisms may, in turn, contribute to de novo generation of
PrPSc in the compartments on the endocytic-recycling pathway.
The intracellular dynamics of PrPSc in CNS neurons in the early
stages after prion infection is largely unknown. It was reported
that PrPSc could be detected in endosomal and lysosomal fractions
prior to the detection of PrPSc in the plasma membrane fraction
after intracerebral inoculation of prions (Dearmond and
Bajsarowicz, 2010), and that protease-sensitive PrPSc could be
detected in early and recycling endosomes in neurons in the
hippocampus during the preclinical stage of infected mice
(Godsave et al., 2008). These facts suggest that there are simila-
rities in prion propagation in neuroblastoma cells and neurons
in CNS.
In this study, we showed the intracellular dynamics of inocu-
lated PrP-res in prion-susceptible neuroblastoma cells. Our data
suggest that transfer of inoculated PrP-res from the endo-
lysosomal pathway to the endocytic-recycling pathway is involved
in the initiation of efﬁcient de novo generation of PrPSc in the early
stage of infection (Fig. 8). However, further analyses are required
for understanding the mechanisms of prion propagation in neu-
rons in CNS. Experiments are underway to clarify the intracellular
site for PrPSc generation in neurons in CNS using PrPSc-speciﬁc
staining with mAb 132.
Materials and methods
Antibodies, expression plasmids, and reagents
Anti-PrP mouse mAbs 31C6 and 132 and a rabbit polyclonal
antibody B103 were used (Horiuchi et al., 1995; Kim et al., 2004).
The other commercially available primary and secondary antibo-
dies that were used for immunoblotting and IFA are listed in Table
S1. Alexa Fluor 488- and 555-conjugated Tfn and Alexa Fluor 488-
conjugated LDL (Life Technologies) were used as markers for the
endocytic pathway. Expression plasmids encoding EGFP-tagged
Rab GTPases were prepared as described in Supplemental materi-
als according to methods described elsewhere (Table S2 and S3)
(Fukuda, 2003).
Cell culture
N2a-3 cells, a subclone of the mouse neuroblastoma cell line
Neuro2a, were cultured as described previously (Uryu et al., 2007).
Puriﬁcation of PrP-res
PrP-res was prepared from detergent-resistant membranes as
described previously (Baron et al., 2011) with slight modiﬁcations
(Supplementary materials). The puriﬁcation procedure included a
PK treatment, so from this point forward we use the term “PrP-
res” to indicate the puriﬁed, PK-treated PrPSc.
Fluorescent-dye-labeling of PrP-res
PrP-res in PBS (10 μg in 50 μl) containing 0.5% Zwittergent 3-14
was sonicated with a Cross Ultrasonic Protein Auto Activating
Instrument, ELSTEIN NP070-GOT (Nepa Gene), by 4 cycles of
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Fig. 8. Summary of intracellular dynamics of inoculated PrPSc and de novo generation of PrPSc in early stage of prion infection. Exogenously introduced PrPSc (red
parallelograms) is internalized into a cell (i). Although inoculated PrPSc is transported throughout endocytic compartment immediately after internalization, most of the
inoculated PrPSc eventually directed to endo-lysosomal pathway (indicated as red arrows) and is delivered to lysosomes and degraded (iii). Conversion of PrPC (pink ellipse)
to PrPSc (pink parallelogram) may be initiated by fragmented inoculated PrPSc (a smaller PrPSc oligomer) that is generated during the transport on the endo-lysosomal
pathway (ii). A smaller PrPSc oligomer generated by fragmentation of inoculated PrPSc and/or newly generated PrPSc is transferred from the endo-lysosomal pathway to the
endocytic-recycling pathway (iv). Once PrPSc that is capable of inducing conversion (blue parallelograms) is transferred to endocytic-recycling pathway (indicated as blue
arrows) initiates efﬁcient PrPSc formation that leads to the establishment of prion infection. The sites where efﬁcient conversion occurs are thought to be early endosomes
and recycling endosomes (v).
T. Yamasaki et al. / Virology 450-451 (2014) 324–335 333
15 min-sonication followed by 5 min-incubation at 4 1C prior to
ﬂuorescent-dye labeling. The PrP-res was then mixed with 200 μg
of Alexa Fluor 488 succinimidyl ester or Alexa Fluor 555 succini-
midyl ester (Life Technologies) dissolved in 5 μl of anhydrous
dimethyl sulfoxide (Sigma). Fluorescent-dye labeling was per-
formed under 16 cycles of 15 min-sonication followed by
30 min-incubation at 4 1C. To quench the excess reactive dye,
3 ml of 50 mM glycine in PBS was mixed with the PrP-res and
the sample was centrifuged at 45,000 rpm for 30 min at 4 1C in a
S80AT3 rotor (Hitachi). The pellet was washed twice with 50 mM
glycine in PBS and each wash was followed by centrifugation; the
ﬁnal pellet was resuspended in 100 μl of PBS with sonication.
The ﬂuorescent-dye-labeled PrP-res or unlabeled PrP-res was
subjected to SDS-PAGE followed by ﬂuorescent imaging with
Typhoon FLA 9000 (GE Healthcare) or by silver-staining with
2D-SILVER STAIN-II (Cosmo bio CO.), respectively.
Inoculation of PrP-res
Puriﬁed PrP-res or ﬂuorescent-dye-labeled PrP-res was diluted
with Opti-MEM (Life technologies), sonicated with an ELSTEIN
NP070-GOT sonicator for 5 min, and centrifuged at 10,000 g for
10 min to remove large PrP-res aggregates. The supernatant was
diluted with Opti-MEM at 10 ng PrP-res/200 μl or 20 ng PrP-res/
250 μl or 35 ng PrP-res/500 μl for use on 8-well Lab-Tek II
chambered coverglass (Thermo Scientiﬁc) or 24- or 12-well plates,
respectively. The culture medium for the N2a-3 cells grown on
a chambered coverglass or in the multi-well plates was replaced
with Opti-MEM containing PrP-res, and the cells were then
incubated for 2 or 6 h at 37 1C. After incubation, the cells were
washed three times with pre-warmed PBS and then cultured in
Opti-MEM containing 10% fetal bovine serum (FBS), 1% non-
essential amino acids (NEAA; Gibco), and 1X penicillin-
streptomycin solution (100 U/ml–100 μg/ml, PS; Gibco).
Immunoﬂuorescence assay (IFA)
IFA, including PrPSc-speciﬁc staining, was carried out as
described previously (Yamasaki et al., 2012) with some modiﬁca-
tions. Cells were grown on an 8-well Lab-Tek II chambered cover-
glass and all the staining procedures were carried out without the
removal of the media chamber. For double staining of cell surface
PrPC and PrPSc, living cells were incubated with B103 (5 μg/ml)
in Opti-MEM for 15 min at 37 1C. The cells were then immediately
ﬁxed with pre-warmed 4% paraformaldehyde with 4% sucrose in
PBS for 10 min and blocked with 5% FBS in PBS. Cells were then
incubated with secondary antibody, and the cells were ﬁxed again
with 4% paraformaldehyde in PBS for 10 min and were subjected
to the PrPSc-speciﬁc staining. To counterstain cell nuclei, cells were
incubated with 5 μg/ml of 4', 6-diamidino-2-phenylindole, dilac-
tate (DAPI; Invitrogen) in PBS at room temperature (rt) for 30 min.
Finally, the media chamber was ﬁlled with PBS and confocal
ﬂuorescent images were acquired with a 63objective lens on a
Zeiss LSM700 inverted microscope and the ZEN 2009 software.
Z-series of the images were taken at every 0.8 μm steps from the
top to bottom of the cells in the area.
Transfection
N2a-3 cells seeded onto 8-well chambered coverglass or 24-
well plates at 1:5 ratio were cultured in Dulbecco's modiﬁed
Eagle's medium (DMEM; ICN Biomedicals) for 2 days prior to the
inoculation of PrP-res and transfection. The cells were transfected
with 2.8% Lipofectamine 2000 (Invitrogen) and 2 μg/ml expression
plasmid in 250 μl (8-well chamber) or 500 μl (24-well plate) of
Opti-MEM that contained 8% FBS, 0.8% NEAA, and 0.8X PS. After
transfection (24 h), the medium was replaced with fresh Opti-
MEM containing 10% FBS, 1% NEAA and 1X PS and cultured until
used for immunoblots or IFA.
Immunoblotting and dot-blotting
Immunoblotting and dot-blotting were performed to monitor
PrP and other molecules as described elsewhere (Nakamitsu et al.,
2010; Uryu et al., 2007). To monitor PrP-res via immunoblotting,
the protein concentration of cell lysate was adjusted to 1 mg/ml
and the samples were then treated with 1 μg/ml of PK for 20 min
at 37 1C. Meanwhile, to monitor Alexa Fluor 488-labeled PrP-res,
PK treatment was omitted. The cell lysates were incubated with
50 μg/ml of DNase I (Roche) for 15 min at rt. Proteins were
concentrated by incubating the samples with 0.3% phosphotungs-
tic acid for 20 min at rt; this incubation was followed by centri-
fugation at 20,500g for 20 min at 4 1C.
To monitor PrP-res via dot-blotting, cell lysate equivalent to
40 μg of total protein per well was transferred onto a polyvinyli-
dene diﬂuoride (PVDF) membrane by a dot-blotter (Bio-Rad). The
PVDF membrane was treated with 20 μg/ml of PK for 1 h at 37 1C
and then incubated with 1 mM Pefabloc SC for 15 min at 4 1C. The
membrane was treated with 50 μg/ml of DNase I for 15 min at rt
and then incubated in 3 M GdnSCN for 30 min at rt. Samples on
each membrane were then subjected to immuno-detection with
mAb 31C6 and HRP-conjugated secondary antibody. ECL Western
Blotting Detection Reagents (GE Healthcare) and a LAS-3000
chemiluminescence image analyzer (Fuji Film) were used to
visualize the immunoreactive proteins.
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